Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Legend Biotech Corporation - American Depositary Shares (NQ: LEGN )

36.45 -1.60 (-4.20%)
Streaming Delayed Price Updated: 12:19 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Why Shares of Geron Are Up 30% This Week
The company's CEO was scheduled to speak at a virtual conference on Thursday. 
Via The Motley Fool
Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names
Where is the current bull market? All indications would be that it's in biotech! The broader market is not really moving. There have been plenty of attention-grabbing headlines, and earnings season is... 
Via Benzinga
7 Biotech Stocks That Could Cure Your Portfolio Woes
If you want to revitalize your portfolio with some exciting opportunities, these biotech stocks to buy might fit the bill. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
The Latest Analyst Ratings for Legend Biotech
Via Benzinga
Where Legend Biotech Stands With Analysts
Via Benzinga
The Latest Analyst Ratings for Legend Biotech
Via Benzinga
Why Travelers Companies Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) gained 85.2% to $1.25 after the company announced the termination of its previously proposed registered direct offering. 
Via Benzinga
Why Shares of Legend Biotech Jumped Wednesday
A leaked abstract on a phase 3 trial for the company's multiple myeloma drug Carvykti gave the stock a jolt. 
Via The Motley Fool
Legend Biotech Corp. (NASDAQ: LEGN) Leading the Way in Wednesday Trading Based on Percentage Gain
Via Investor Brand Network
4 Analysts Have This to Say About Legend Biotech
Via Benzinga
Legend Biotech Breaks Out After Leaked Documents Show Big CAR-T Benefit
The company could have the best-in-class CAR-T drug for multiple myeloma patients. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Western Alliance Bancorporation, Intuitive Surgical And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pre-market trading session. Western Alliance Bancorporation (NYSE: WAL) shares jumped 15.4% to $37.50... 
Via Benzinga
Legend Biotech Announces Appointment of Chief Medical Officer
From Legend Biotech
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Legend Biotech Establishes Strategic Advisory Board
From Legend Biotech
Via Business Wire
Legend Biotech Reports Full-Year 2022 Results and Recent Highlights
From Legend Biotech
Via Business Wire
7 Biotech Stocks to Buy for Breakthrough Treatments and Cures
For those that can handle the heat, these biotech stocks to buy undergird some of the most powerful innovations in medicine. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For March 29, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2023
Via Benzinga
Legend Biotech Announces Participation in Upcoming Investor Conferences
From Legend Biotech
Via Business Wire
Legend Biotech Regains Compliance with NASDAQ Listing Rule 5250(c)(2)
From Legend Biotech
Via Business Wire
Week In Review: HutchMed Announces $1.1 Billion Deal With Takeda For Colorectal Cancer Drug
Shanghai’s HutchMed out-licensed global rights for a colorectal cancer therapy to Japan’s Takeda in a deal worth up to $1.13 billion, including $400 million upfront. In addition to the $1.13 billion,... 
Via Talk Markets
Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI® (ciltacabtagene autoleucel) Has Met Its Primary Endpoint in the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
From Legend Biotech
Via Business Wire
Legend Biotech to Participate in the 41st Annual JP Morgan Healthcare Conference
From Legend Biotech
Via Business Wire
Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China
From Legend Biotech
Via Business Wire
Gracell Biotech Stock Has Over 100% Upside On Next-Gen CAR-T Platforms, Analyst Claims
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2022
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.